Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2014 - 2026)

Dr Reddys Laboratories' Non-Current Deferred Tax Liability history runs 13 years deep, the most recent figure standing at $170.3 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 4.53% year-over-year to $170.3 million; the TTM figure through Mar 2026 stood at $170.3 million (up 4.53% YoY), while the FY2026 annual figure was $166.0 million, up 0.61% from the prior year.
• Non-Current Deferred Tax Liability was $170.3 million for Q1 2026 at Dr Reddys Laboratories, roughly flat from $170.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $170.3 million in Q1 2026 to a low of $576967.2 in Q3 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $76.9 million across 5 years, with a median of $10.9 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deferred Tax Liability sank 82.79% in 2022, then jumped 13282.2% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $576967.2 in 2022, then soared by 113.86% to $1.2 million in 2023, then surged by 13282.2% to $165.1 million in 2024, then rose by 2.95% to $170.0 million in 2025, then gained by 0.18% to $170.3 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $170.3 million (Q1 2026), $170.0 million (Q3 2025), and $162.9 million (Q1 2025), per Business Quant data.